Providing solutions to complex
of new drugs are
Increasing solubility and bioavailability
Low drug compound solubility is a major cause of attrition in the pharmaceutical industry. We help drugs reach their full therapeutic potential by enhancing bioavailability. NanoformingTM increases the active surface area of API particles, enabling significant improvements in dissolution rate and bioavailability. The creation of a robust method for producing uniform and stable nanoparticles has initiated a new era of novel drug delivery applications that will transform the healthcare sector.
The benefits of our best-in-class nanoformingTM services
Nanoforming increases the rate of dissolution and improves bioavailability, leading to a reduction in the number of drugs that fail to reach clinical trials because of low solubility. Increased bioavailability also lowers the dosage required for a therapeutic effect, resulting in a reduction in side effects.
Additional drug delivery applications
The efficient production of nanoparticles is leading to exciting new drug delivery applications. Our nanoforming technology can produce nanoparticles small enough to cross the blood-brain barrier (BBB) for treatment of central nervous system disorders, such as ALS, Alzheimer’s disease and Parkinson’s disease. Nanoparticles can also be used for novel applications in ocular and transdermal drug delivery, along with drug penetration into the deep lung.
Our particle engineering services can provide a change in formulation to improve the performance of current drugs on the market. The commercial opportunities of our work include life cycle extension, additional patent protection and the creation of barriers to generic competition.
Global experts in
drug particle engineering
We first perform an initial evaluation to understand compound characteristics. Our extensive conversations with partners enable us to fully define what we aim to achieve and the challenges involved.
Proof of concept
A proof of concept study is initiated to determine the feasibility of nanoforming the material. A proof of process study is then performed to find the optimal process parameters for consistent, reproducible results.
Scalability assessment and manufacture
A demonstration batch is produced at a larger scale before being moved into our GMP facilities for clinical production.